...
arvn-img

Arvinas Inc, Common Stock

ARVN

NSQ

$18.48

+$0.65

(3.65%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.23B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.71M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.97
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$17.37 L
$53.08 H
$18.48

About Arvinas Inc, Common Stock

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameARVNSectorS&P500
1-Week Return-5.23%-2.12%-3%
1-Month Return-18.55%-3.42%-0.73%
3-Month Return-27.9%-11.13%2.87%
6-Month Return-26.96%-5.74%7.17%
1-Year Return-49.3%3.97%25.31%
3-Year Return-75.36%1.05%28.38%
5-Year Return-53.45%34.37%81.89%
10-Year Return15.14%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue42.98M21.80M46.70M131.40M78.50M[{"date":"2019-12-31","value":32.71,"profit":true},{"date":"2020-12-31","value":16.59,"profit":true},{"date":"2021-12-31","value":35.54,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.74,"profit":true}]
Cost of Revenue--6.00M8.20M6.70M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":73.17,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":81.71,"profit":true}]
Gross Profit42.98M21.80M46.70M131.40M78.50M[{"date":"2019-12-31","value":32.71,"profit":true},{"date":"2020-12-31","value":16.59,"profit":true},{"date":"2021-12-31","value":35.54,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.74,"profit":true}]
Gross Margin100.00%100.00%100.00%100.00%100.00%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses94.50M146.66M242.00M394.60M480.00M[{"date":"2019-12-31","value":19.69,"profit":true},{"date":"2020-12-31","value":30.55,"profit":true},{"date":"2021-12-31","value":50.42,"profit":true},{"date":"2022-12-31","value":82.21,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(51.52M)(124.86M)(195.30M)(263.20M)(401.50M)[{"date":"2019-12-31","value":-5152451400,"profit":false},{"date":"2020-12-31","value":-12485747700,"profit":false},{"date":"2021-12-31","value":-19530000000,"profit":false},{"date":"2022-12-31","value":-26320000000,"profit":false},{"date":"2023-12-31","value":-40150000000,"profit":false}]
Total Non-Operating Income/Expense(14.30M)9.05M6.10M24.40M69.90M[{"date":"2019-12-31","value":-20.45,"profit":false},{"date":"2020-12-31","value":12.94,"profit":true},{"date":"2021-12-31","value":8.73,"profit":true},{"date":"2022-12-31","value":34.91,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(70.29M)(119.33M)(191.00M)(251.00M)(363.90M)[{"date":"2019-12-31","value":-7029222700,"profit":false},{"date":"2020-12-31","value":-11933206400,"profit":false},{"date":"2021-12-31","value":-19100000000,"profit":false},{"date":"2022-12-31","value":-25100000000,"profit":false},{"date":"2023-12-31","value":-36390000000,"profit":false}]
Income Taxes(8.16M)(7.55M)(7.80M)20.90M900.00K[{"date":"2019-12-31","value":-39.04,"profit":false},{"date":"2020-12-31","value":-36.1,"profit":false},{"date":"2021-12-31","value":-37.32,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":4.31,"profit":true}]
Income After Taxes(62.13M)(111.79M)(183.20M)(271.90M)(364.80M)[{"date":"2019-12-31","value":-6213203800,"profit":false},{"date":"2020-12-31","value":-11178670600,"profit":false},{"date":"2021-12-31","value":-18320000000,"profit":false},{"date":"2022-12-31","value":-27190000000,"profit":false},{"date":"2023-12-31","value":-36480000000,"profit":false}]
Income From Continuous Operations(70.29M)(119.33M)(191.00M)(282.50M)(295.40M)[{"date":"2019-12-31","value":-7029222700,"profit":false},{"date":"2020-12-31","value":-11933206400,"profit":false},{"date":"2021-12-31","value":-19100000000,"profit":false},{"date":"2022-12-31","value":-28250000000,"profit":false},{"date":"2023-12-31","value":-29540000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(62.13M)(111.79M)(183.20M)(271.90M)(367.30M)[{"date":"2019-12-31","value":-6213203800,"profit":false},{"date":"2020-12-31","value":-11178670600,"profit":false},{"date":"2021-12-31","value":-18320000000,"profit":false},{"date":"2022-12-31","value":-27190000000,"profit":false},{"date":"2023-12-31","value":-36730000000,"profit":false}]
EPS (Diluted)(1.36)(2.99)(3.81)(5.32)(6.50)[{"date":"2019-12-31","value":-136,"profit":false},{"date":"2020-12-31","value":-299,"profit":false},{"date":"2021-12-31","value":-381,"profit":false},{"date":"2022-12-31","value":-532,"profit":false},{"date":"2023-12-31","value":-650,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ARVN
Cash Ratio 4.07
Current Ratio 4.17

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ARVN
ROA (LTM) -20.07%
ROE (LTM) -59.16%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ARVN
Debt Ratio Lower is generally better. Negative is bad. 0.50
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.50

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ARVN
Trailing PE NM
Forward PE 17.70
P/S (TTM) 7.60
P/B 2.18
Price/FCF NM
EV/R 0.98
EV/Ebitda NM

FAQs

What is Arvinas Inc share price today?

Arvinas Inc (ARVN) share price today is $18.48

Can Indians buy Arvinas Inc shares?

Yes, Indians can buy shares of Arvinas Inc (ARVN) on Vested. To buy Arvinas Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ARVN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Arvinas Inc be purchased?

Yes, you can purchase fractional shares of Arvinas Inc (ARVN) via the Vested app. You can start investing in Arvinas Inc (ARVN) with a minimum investment of $1.

How to invest in Arvinas Inc shares from India?

You can invest in shares of Arvinas Inc (ARVN) via Vested in three simple steps:

  • Click on Sign Up or Invest in ARVN stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Arvinas Inc shares
What is Arvinas Inc 52-week high and low stock price?

The 52-week high price of Arvinas Inc (ARVN) is $53.08. The 52-week low price of Arvinas Inc (ARVN) is $17.37.

What is Arvinas Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Arvinas Inc (ARVN) is

What is Arvinas Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Arvinas Inc (ARVN) is 2.18

What is Arvinas Inc dividend yield?

The dividend yield of Arvinas Inc (ARVN) is 0.00%

What is the Market Cap of Arvinas Inc?

The market capitalization of Arvinas Inc (ARVN) is $1.23B

What is Arvinas Inc’s stock symbol?

The stock symbol (or ticker) of Arvinas Inc is ARVN

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top